Stock YP1A IMMUTEP ADR
Add to a list
To use this feature you must be a member
Log inSign up

News Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Market Closed - Deutsche Boerse AG
Other stock markets
 02:05:16 2024-06-14 am EDT 		5-day change 1st Jan Change
2.5 EUR +6.84% Intraday chart for Immutep ADR -0.79% +17.92%
Jun. 05 Immutep Completes Stock Offering MT
Jun. 03 Immutep, Merck Collaborate on Trial for Lung Cancer Therapy MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immutep Completes Stock Offering
MT
Immutep : successfully completes institutional placement and institutional component of entitlement offer
PU
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy
MT
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial
MT
Immutep Raising AU$100 Million for Phase Three Trial
MT
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
AQ
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial
CI
Capital One Initiates Immutep at Overweight Rating With $10 Price Target
MT
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data
MT
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
AQ
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024
CI
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)
PU
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO
CI
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
AQ
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial
MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024
CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00
MT
Immutep Quarterly Activities Report Q3 FY24
AQ
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. YP1A Stock
  5. News Immutep ADR